Akeso Begins Phase I Trial for Personalized mRNA Vaccine Against Pancreatic Cancer Akeso, Inc. has initiated a Phase I clinical trial for its personalized mRNA vaccine, AK154, aimed at treating pancreatic cancer, both alone and with bispecific antibodies.

Akeso Begins Phase I Trial for Personalized mRNA Vaccine Against Pancreatic Cancer #Cadonilimab #Ivonescimab #AK154